Clinical positioning and future prospects of JAK inhibitors in alopecia areata.

INTRODUCTION: Alopecia areata (AA) is a chronic autoimmune disease characterized by non-scarring hair loss driven by cytotoxic attack against anagen hair follicles. Janus kinase (JAK) inhibitors disrupt the pathogenic signaling and have revolutionized treatment landscape for severe AA. Nevertheless, clinical unmet needs remain for the primary non-responders, relapse during treatment, and lack of reliable biomarkers to guide treatment discontinuation.

AREAS COVERED: This review summarizes evidence from pivotal clinical trials and real-world studies of JAK inhibitors in AA.  Post-hoc analyses addressing relapse after withdrawal, and dose reduction are also discussed. Furthermore, we overview real-world data highlighting clinical factors associated with treatment responses. A literature search was conducted primarily in PubMed for articles published up to November 2025, with additional website searches for company announcements and clinical trial related updates when relevant.

EXPERT OPINION: JAK inhibitors have redefined the therapeutic framework for severe AA and serve as the functional probes that clarify disease biology underlying AA. Emerging evidence suggests that early intervention and standardized monitoring based on clinical information should guide treatment design. Future challenges include systematizing strategies for continuation, dose reduction, temporary interruption, and reinitiation based on patient background, as well as developing more effective combination therapies.